Sareum Holdings Plc (LON:SAR) chief executive, Dr Tim Mitchell, talked to Proactive Investors' Andrew Scott about Sierra Oncology, which is the licence-holder for the Sareum-developed SRA737 cancer drug.
Mitchell said he's heartened Sierra is more than doubling the size of two phase II clinical trials of the treatment (one underway, the other upcoming).
He is also impressed by the methodology used by Sierra's researchers that is hoped will glean the best results.
"Rather than screen all-comers they [Sierra] are looking to pre-screen patients for mutations that are most likely to respond to CHK-1 [checkpoint kinase 1] inhibitors so the chances of seeing efficacy we hope are very good," he told Proactive's Scott.
Meet Wolf Minerals, Thor Mining PLC, Rainbow Rare Earths Limited and Caledonia Mining Corporation at our event,London, 22 March 2018.Register here >>